Facts&figures of pharmaceutical industry in Italy. June 2016

Transcription

1 Facts&figures of pharmaceutical industry in Italy June 2016

2 Key figures of pharma sector in Italy (% on total), member of Farmindustria, representing 90% of industrial value of pharmaceutical sector in Italy 43% women, and in (90% graduates),, 53% women billion of 73% of which due to export ( 22 billions) Note: average of turnover, employees, investments in manufacturing and R&D, foreign sales, taxation billion in, 1.4 of which in R&D and 1.2 in hi-tech plants and machinery Source: elaboration of Istat, Eurostat data

3 Pharmaceutical and upstream sectors by Regions Lombardy 28,000 direct employees, Lombardia ranks 1 st for pharmaceutical and biotech firms; 18,000 employees in upstream industries (chemicals, machinery, paper) Piedmont and Liguria 2,000 direct employees and 7,000 in upstream industries (machinery, chemicals, packaging) Tuscany 6,000 direct employees 4,000 employees in upstream industries (glass, chemicals) Lazio 16,000 direct employees 47% of regional export (87% of hi-tech export) 6,000 employees in upstream industries (chemicals, packaging) Fact&figures of pharmaceutical industry and upstream sectors in Italy 130,000 employees 6.6 bln of salaries (including social contributions) 44 bln of production value 3,4 bln of R&D, plants and machinery investments Veneto 3,000 employees, 7,000 in upstream industries (machinery, chemicals, packaging) Emilia Romagna 3,600 direct employees and 7,000 in upstream suppliers (machinery, chemicals, glass). Parma: pharma ranks third for export Campania 900 direct employees and 3,000 in upstream industries Marche 2,900 employees in pharma companies and upstream suppliers. Ancona: export to more than 40 countries Ascoli Piceno: pharma accounts for 70% of total export Abruzzo 1,400 direct employees (100 in R&D) and 1,300 in allied industry Puglia Centres of excellence of major international companies (3,000 employees in pharma companies and related industries). Bari and Brindisi pharma export accounts for 25% of total Sicily About 1,000 direct employees and 2,500 in related industries. Catania: pharma accounts for 14% of total export Source: elaboration of Farmindustria, Istat data

4 Italy is the second pharma manufacturer in EU (aiming at becoming the first) 35 ( billion, 2015 estimates) In 2015, with the expectation to become the first manufacturer in the medium-term Among the Big Eu Italy accounts for and 19% of total sales 0 Source: elaboration of Istat, Efpia data

5 The role of pharmaceutical industry in Italy for the economy of the country (var. %) 12% 10% 8% 6% 4% 2% 0% -2% -4% -6% The comparison with GDP shows the importance of the pharmaceutical industry for Italy s economy Furthermore, from 2010 to 2015 the pharma ranks first among manufacturing sectors for growth of: (manufacturing average: -7%) (+57%) (manufacturing average: +23%) (+21%) (manufacturing average: +5%) (+11%) Pharmaceutical production GDP (*) labour productivity: added value per employee Source: elaboration of Istat data

6 The largest growth of export in Europe: export as the engine of pharma companies in Italy (% change) From 2010 to 2015 pharma export in Italy has grown The performance of export is the result of an : in the average value at export registered a growth of +34% (compared to +22% of Eu average): 0% 10% 20% 30% 40% 50% 60% Source: elaboration of Istat, Eurostat data

7 The growth of employment in pharma sector (index: n of hirings in 2015=100) In 2015 employment in pharma industry, mainly in production and R&D (+3%) in 2015 (+20% compared to average) contributed to the employment increase 70 The is the main competitive advantage for pharma companies and their investments in Italy Fonte: elaboration of Istat, Farmindustria data

8 Foreign-owned pharma companies in Italy: leaders for investments and export ( billion) Mechanics Chemical Transport Oil & gas Metal products Electronics Rubber & plastic Food & beverages Textile & clothes Computers Glass & ceramic products Wood, paper & print Furniture Among foreign-owned companies in Italia, pharma ranks top for And they are also leader for: share of export on production (90%) 0 4,000 8,000 10,000 16,000 Source: elaboration of Istat data

9 Italian-owned pharma companies in Italy: performances beyond the manufacturing average (index: total manufacturing=100) Among Italian-owned companies, pharmaceutical has This structural features allow companies to expand to foreign markets: in fact, they exported Value added Investments in production and R&D Pharmaceutical industry Manufacturing industry Source: elaboration of Istat data

10 Pharma research in Italy: a network of excellence for health and quality of life (for many diseases) Cancers Neurological disorders Infectious diseases Immunological disorders Cardiovascular diseases Mental health disorders Diabetes HIV/AIDS More than 7,000 medicines in development globally, : in (324 products in development),,,, and between companies and public-private,, universities. As demonstrated by two examples of excellence: the first medicine in the world based on staminal cells is Italian the first genic-therapy medicines is Italian Source: Farmindustria, EY, PhRMA

11 R&D pharma investment in Italy are growing also thanks to a more attractive ecosystem ( million) 1,450 1,400 1,350 In 2015 pharma companies invested, the In the last two years investments have grown by 15%, and 75% of companies claim an 1,300 1,250 1,200 1,150 Pharma companies in Italy invest 15% of their added value, 10 times more than the national average. The sector drives the country to 1, Source: elaboration of Farmindustria, Istat, Bain&Company data

12 Clinical trials: the door of innovation, opportunity and resource for the country (% on total) In 2015 pharma companies invested, in NHS structures Italy could become a, thanks to the scientific expertise and the excellences in industry, universities and NHS structures Investing in clinical trials not only means : it also , since companies bear all the costs connected to clinical trials (for 1 invested in oncology trials, NHS saves 2,2 ) Source: elaboration of Farmindustria, Aifa data

13 Italy in international comparisons: HC and pharma expenditure lower than big Eu (US dollars) (territorial + hospital, euro, 2015) Source: elaboration of Aifa, Cergas-Bocconi, IMS, Eurostat, OECD data

14 Pharma expenditure in Italy: -0.3% since 2010, 30% lower than other big Eu (per capita) ( % change) (excl. personnel) From 2010 to 2015 pharmaceutical public expenditure, while HC expenditure has increased (+0.8%) Pharma public expenditure is (per capita) -4.0% -3.0% -2.0% -1.0% 0.0% 1.0% 2.0% (*) net to payed by companies Source: elaboration of Istat, Aifa data

15 Lower in-patent and off-patent prices in pharmacies and hospitals in comparison to Eu countries (bilateral comparisons, total market, index Italy=100) Total market Pharmacy channel Total in-patent off-patent Hospital Source: Cergas Bocconi on IMS data

16 Conditions at market launch for new medicines in Italy and other big European countries (time elapsing between EMA s MAs and availability) Access to new medicines in Italy is penalized compared to other big Eu countries. This gap is due to the Measured in terms of per capita consumptions, the availability of new medicines to patients is reduced as compared to other big Eu countries Source: elaboration of Farmindustria su dati Efpia, Aifa data

17 Pharmaceutical industry and upstream sectors in Italy ( billion, ex-factory prices) Pharmaceutical industry Upstream sectors Investments, Production and R&D Wages and social security contributions (*) Direct tax, other taxes (**) and VAT (*) excluding R&D employees, included in «R&D investments» (**) Fares, duties and non-deductible calculated on expenditure in promotional events and conventions Source: elaboration and estimates of Aifa, Farmindustria, Istat data